Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Joseph A M J L Janssen"'
Autor:
Joseph A M J L Janssen, Leo J Hofland, Christian J Strasburger, Elisabeth S R van den Dungen, Mario Thevis
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0150453 (2016)
To compare full-length mechano growth factor (full-length MGF) with human recombinant insulin-like growth factor-I (IGF-I) and human recombinant insulin (HI) in their ability to activate the human IGF-I receptor (IGF-IR), the human insulin receptor (
Externí odkaz:
https://doaj.org/article/861bef6bed8f4660b032fd982a604384
Autor:
Joseph A. M. J. L. Janssen
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 10, p 5488 (2024)
The worldwide incidence of prediabetes/type 2 has continued to rise the last 40 years. In the same period, the mean daily energy intake has increased, and the quality of food has significantly changed. The chronic exposure of pancreatic β-cells to c
Externí odkaz:
https://doaj.org/article/aac3c7cd97e647c9a46694aa1d482d76
Autor:
Joseph A. M. J. L. Janssen
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 5, p 4551 (2023)
The metabolic syndrome is a cluster of overlapping conditions resulting in an increased incidence of type 2 diabetes, cardiovascular disease, and cancer. In the last few decades, prevalence of the metabolic syndrome in the Western world has reached e
Externí odkaz:
https://doaj.org/article/d86bbbdf7928429ea0ed5e1aa652f4ad
Autor:
Şeyda Berk, Joseph A. M. J. L. Janssen, Peter M. van Koetsveld, Fadime Dogan, Naci Değerli, Servet Özcan, Fahrettin Kelestimur, Leo J. Hofland
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
There are only a few experimental studies which have investigated effects of glucose alone, and glucose in combination with insulin/insulin-like growth factors (IGF) on the growth of colon cancer. In the present study, we studied in vitro in human co
Externí odkaz:
https://doaj.org/article/43c77b5f198b45df994fe31a982172e4
Publikováno v:
Journal of Clinical Endocrinology and Metabolism, 107, S1-S12. Endocrine Society
Context Thyroid eye disease (TED) is a complex autoimmune disease process. Orbital fibroblasts represent the central orbital immune target. Involvement of the TSH receptor (TSHR) in TED is not fully understood. IGF-I receptor (IGF-IR) is overexpresse
Autor:
Joseph A. M. J. L. Janssen
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 15, p 7797 (2021)
For many years, the dogma has been that insulin resistance precedes the development of hyperinsulinemia. However, recent data suggest a reverse order and place hyperinsulinemia mechanistically upstream of insulin resistance. Genetic background, consu
Externí odkaz:
https://doaj.org/article/76273d2438c64af1863098fd3fa2aeba
Autor:
Terry J. Smith, Joseph A M J L Janssen
Publikováno v:
Endocrine Reviews, 40(1), 236-267. The Endocrine Society
Thyroid-associated ophthalmopathy (TAO) is a complex disease process presumed to emerge from autoimmunity occurring in the thyroid gland, most frequently in Graves disease (GD). It is disfiguring and potentially blinding, culminating in orbital tissu
Autor:
Ammar Muhammad, Eva C Coopmans, Sebastian J C M M Neggers, Aart Jan van der Lely, Joseph A M J L Janssen
Publikováno v:
Journal of Clinical Endocrinology and Metabolism, 104(6), 1978-1988. Endocrine Society
Context Pasireotide long-acting release (LAR) is a somatostatin multireceptor ligand, and in the current consensus criteria pasireotide LAR is considered the second-line medical treatment for acromegaly. We present in this article our recommendations
Autor:
Casper Hammarstrand, Gudmundur Johannsson, Selvetta S van Santen, Mark Wijnen, Marry M. van den Heuvel-Eibrink, Daniel S Olsson, Aart Jan van der Lely, Joseph A M J L Janssen, Sebastian J C M M Neggers
Publikováno v:
European Journal of Endocrinology, 181(2), 173-183. Bioscientifica Ltd
Objective Craniopharyngioma patients often have poor metabolic profiles due to hypothalamic–pituitary damage. Previously, using BMI as obesity marker, the occurrence of the metabolic syndrome in these patients was estimated at 46%. Our aim was to d
Autor:
Patric J.D. Delhanty, Sebastian J C M M Neggers, Iain K. Haitsma, Eva C Coopmans, Alof H G Dallenga, Joseph A M J L Janssen, Aart Jan van der Lely, Ammar Muhammad
Publikováno v:
European Journal of Endocrinology, 179(5), 269-277. Bioscientifica Ltd
ObjectiveTo assess the efficacy and safety after 48 weeks of treatment with pasireotide long-acting-release (PAS-LAR) alone or in combination with pegvisomant in patients with acromegaly. In addition, we assessed the relation between insulin secretio